Powered by

Karyopharmâ(EURO)(TM)s selinexor combination for multiple myeloma unlikely to see second-line use despite likely FDA approval

Dec 18, 2020 - Marketline Newswire

By William Newton

Karyopharm Therapeuticsâ(EURO)(TM) selinexor, combined with bortezomib and dexamethasone (SVd), will likely see limited use as a second-line therapy for multiple myeloma (MM) even though FDA approval is expected, experts said. The SVd combination, which was used in the treatment group in the Phase III BOSTON trial (NCT03110562), would not be viable for many patients due to the prevalence of bortezomib in induction therapies, leading to cross-resistance, experts not...